Breton Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Seattle-based Shape Therapeutics raises $112M to develop RNA-editing and gene therapies Geekwire 3 hrs ago © Provided by Geekwire Shape CEO Francois Vigneault. (Shape Photo) Shape Therapeutics, a Seattle preclinical stage biotech company developing RNA editing and gene therapy technologies, has raised $112 million. The company’s RNA editing technologies are spun out of the lab of co-founder Prashant Mali, a bioengineer at the University of California, San Diego who is on Shape’s scientific advisory board. Shape is also improving methods to deliver genetic material into cells. “We continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases,” said CEO and co-founder Francois Vigneault, former VP of research at Juno Therapeutics, a Seattle flagship cell therapy company that was acquired by Celgene in 2018. Other Juno veterans at the company include Adrian Briggs, head of platform technologies, and David Huss, vice presi

United statesSan diegoLou gehrigFrancois vigneaultKorro bioDon clevelandDavid hussHadrian briggsUniversity of californiaEnterprise associatesBreakthrough prize in life sciencesMission biocapitalShape photoGeekwire shapePrashant maliJuno therapeutics